• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Revvity Inc.

    4/25/25 4:06:40 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $RVTY alert in real time by email
    8-K
    false 0000031791 --12-29 0000031791 2025-04-22 2025-04-22 0000031791 us-gaap:CommonStockMember 2025-04-22 2025-04-22 0000031791 us-gaap:DeferrableNotesMember 2025-04-22 2025-04-22
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): April 22, 2025

     

     

    Revvity, Inc.

    (Exact Name of Registrant as Specified in its Charter)

     

     

     

    Massachusetts   001-05075   04-2052042

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    77 4th Avenue, Waltham, Massachusetts   02451
    (Address of Principal Executive Offices)   (Zip Code)

    Registrant’s telephone number, including area code: (781) 663-6900

    Not applicable.

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

      ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

      ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

      ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

      ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol

     

    Name of exchange

    on which registered

    Common stock, $1 par value per share   RVTY   The New York Stock Exchange
    1.875% Notes due 2026   RVTY26   The New York Stock Exchange

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 5.03

    Amendments to Articles of Organization or Bylaws; Change in Fiscal Year

    At the annual meeting of shareholders of Revvity, Inc. (the “Company”) held on April 22, 2025, the shareholders voted on and approved a proposal to amend the Company’s Restated Articles of Organization, as amended (the “Articles of Organization”), to implement a majority voting standard for specified corporate actions (the “Majority Voting Standard”). On April 23, 2025, the Company filed articles of amendment to the Articles of Organization (the “Articles of Amendment”) with the Secretary of the Commonwealth of Massachusetts (the “Secretary of the Commonwealth”) to effect the amendments to the Articles of Organization approved by the shareholders. Subsequently, on the same day, the Company filed articles of correction to the Articles of Organization (the “Articles of Correction”) with the Secretary of the Commonwealth to include a page of the Articles of Amendment that was included in the Company’s transmission of the Articles of Amendment to the Secretary of the Commonwealth but which was not received by the Secretary of the Commonwealth. Copies of the Articles of Amendment and the Articles of Correction, both effective as of April 23, 2025, are attached hereto as Exhibit 3.1 and Exhibit 3.2, respectively, and incorporated herein by reference.

    In connection with the Majority Voting Standard, the board of directors of the Company approved an amendment and restatement of the Company’s Amended and Restated By-laws (prior to such amendment and restatement, the “Prior By-laws”) to, among other updates, implement the Majority Voting Standard (as amended and restated, the “Amended and Restated By-laws”) effective as of April 24, 2025. A copy of the Amended and Restated By-laws, in redline form to show the amendments made by the Company to the Prior By-laws, is attached hereto as Exhibit 3.3 and incorporated herein by reference.

     

    Item 5.07

    Submission of Matters to a Vote of Security Holders.

    At the annual meeting of shareholders of the Company held on April 22, 2025, the shareholders voted on the following proposals:

     

      •  

    a proposal to elect the ten nominees for director named below for terms of one year each;

     

      •  

    a proposal to ratify the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the current fiscal year;

     

      •  

    a proposal to approve, by non-binding advisory vote, the Company’s executive compensation;

     

      •  

    a proposal to amend the Company’s Restated Articles of Organization, as amended, and the Company’s Amended and Restated By-laws to implement the Majority Voting Standard; and

     

      •  

    a shareholder proposal regarding ability to call special shareholder meeting.

    The shareholders elected each of the nominees to serve as a director for a term of one year. The final number of votes cast for or against or abstaining and the number of broker non-votes for each nominee are listed below. The proposal to ratify the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm, the proposal to approve, by non-binding advisory vote, the Company’s executive compensation, and the proposal to amend the Company’s Restated Articles of Organization, as amended, and the Company’s Amended and Restated By-laws to implement the Majority Voting Standard were also approved. The final number of votes cast for or against or abstaining from voting on those three proposals and the number of broker non-votes on the executive compensation proposal and the Majority Voting Standard proposal are listed below. The shareholder proposal regarding ability to call special shareholder meeting was approved. The final number of votes cast for or against or abstaining from voting and the number of broker non-votes on that proposal are listed below.


    Proposal #1 – To elect the following nominees as our directors for terms of one year each:

     

    Name    Votes in Favor      Votes Against      Abstentions      Broker Non-Votes  

    Peter Barrett, PhD

         97,163,257        4,306,671        54,311        4,155,796  

    Samuel R. Chapin

         100,030,553        1,420,897        72,789        4,155,796  

    Michael A. Klobuchar

         101,183,877        280,115        60,247        4,155,796  

    Michelle McMurray-Heath, MD, PhD

         101,281,324        193,378        49,537        4,155,796  

    Alexis P. Michas

         98,367,736        3,103,143        53,360        4,155,796  

    Prahlad R. Singh, PhD

         101,268,785        197,380        58,074        4,155,796  

    Sophie V. Vandebroek, PhD

         101,272,302        198,804        53,133        4,155,796  

    Michael Vounatsos

         98,842,306        2,608,120        73,813        4,155,796  

    Frank Witney, PhD

         100,141,849        1,322,316        60,074        4,155,796  

    Pascale Witz

         101,267,012        197,912        59,315        4,155,796  

    Proposal #2 – To ratify the selection of Deloitte & Touche LLP as the Company’s independent public accounting firm for the current fiscal year.

     

    For   Against   Abstain   Broker Non-Votes
    103,598,283   1,968,762   112,990   0

    Proposal #3 – To approve, by non-binding advisory vote, the Company’s executive compensation.

     

    For   Against   Abstain   Broker Non-Votes
    92,835,062   8,444,564   244,613   4,155,796

    Proposal #4 – To amend the Company’s Restated Articles of Organization, as amended, and the Company’s Amended and Restated By-laws to implement the Majority Voting Standard.

     

    For   Against   Abstain   Broker Non-Votes
    98,409,372   363,712   2,751,155   4,155,796

    Proposal #5- Shareholder proposal regarding ability to call special shareholder meeting.

     

    For   Against   Abstain   Broker Non-Votes
    66,916,220   35,272,422   335,597   4,155,796


    Item 9.01.

    Financial Statements and Exhibits.

    (d) Exhibits

     

    Exhibit
    No.

      

    Description

    3.1    Articles of Amendment to Restated Articles of Organization, as amended, effective as of April 23, 2025.
    3.2    Articles of Correction to Restated Articles of Organization, as amended, effective as of April 23, 2025.
    3.3    Amended and Restated By-laws, redlined for amendments effective as of April 24, 2025.
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document).


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        REVVITY, INC.
    Date: April 25, 2025     By:  

    /s/ John L. Healy

          John L. Healy
          Vice President and Assistant Secretary
    Get the next $RVTY alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $RVTY

    DatePrice TargetRatingAnalyst
    5/1/2025$115.00Neutral → Buy
    UBS
    1/10/2025$130.00Outperform → Mkt Perform
    Bernstein
    12/13/2024$138.00Neutral → Buy
    BofA Securities
    10/15/2024$125.00 → $140.00Equal Weight → Overweight
    Barclays
    8/28/2024$130.00Equal Weight
    Wells Fargo
    7/8/2024$125.00Outperform
    Leerink Partners
    6/3/2024$115.00Hold
    Jefferies
    1/16/2024$105.00 → $125.00Buy → Neutral
    UBS
    More analyst ratings

    $RVTY
    SEC Filings

    See more
    • SEC Form 11-K filed by Revvity Inc.

      11-K - REVVITY, INC. (0000031791) (Filer)

      6/20/25 2:18:15 PM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SD filed by Revvity Inc.

      SD - REVVITY, INC. (0000031791) (Filer)

      5/30/25 8:00:26 AM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 10-Q filed by Revvity Inc.

      10-Q - REVVITY, INC. (0000031791) (Filer)

      5/6/25 4:07:57 PM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $RVTY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Revvity Introduces New IVD Reference Standards for Monitoring Oncology Diagnostic Testing Workflows

      Revvity launches its first set of IVD Mimix reference standards, providing diagnostic labs with trusted quality controls for optimizing tests and monitoring workflows Revvity, Inc. (NYSE:RVTY), today announced the launch of three Mimix™ reference standards for IVD use, designed for monitoring of next-generation sequencing (NGS) or droplet digital polymerase chain reacting (ddPCR) assays designed to detect somatic mutations in genomic DNA (gDNA) from human samples for IVD use. These cell line-derived reference standards have undergone appropriate design controls to meet U.S. Food and Drug Administration (FDA) regulatory requirements, which helps laboratories integrate them into existing wo

      6/2/25 8:00:00 AM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • AstroNova Sends Letter to Shareholders Highlighting Growth Strategy and Strength of Board

      AstroNova is at critical inflection point in its strategic progress to create meaningful competitive advantages for the Product Identification segment and drive strong, sustainable growth, improved profitability and address measurably larger addressable markets Askeladden/Patel's misguided, upstart campaign is disrupting progress and his unfit nominees stand to siderail advancement Urges shareholders to vote "FOR" ONLY AstroNova's Board nominees on the WHITE proxy card Current leadership has transformed AstroNova's capabilities, product mix, and scale, delivering 7.5% compound annual revenue growth since Gregory Woods' appointment as CEO AstroNova, Inc. (NASDAQ:ALOT), a leading innovat

      5/19/25 5:00:00 PM ET
      $ALNT
      $ALOT
      $BWA
      $RVTY
      Electrical Products
      Industrials
      Computer peripheral equipment
      Technology
    • Revvity's EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing

      The IDS i20 platform offers fully automated processing of specialty assays in endocrinology, allergy, autoimmune and infectious diseases, Alzheimer's disease and therapeutic drug monitoring Revvity, Inc. (NYSE:RVTY), today announced the launch of its new IDS i20™ analytical random access platform from EUROIMMUN, enabling full automation of chemiluminescence immunoassays (ChLIA). The IDS i20 platform is a CE marked and FDA listed device that allows laboratories to consolidate multiple specialty tests on a unique single instrument with greater reagent capacity and higher test throughput compared to existing offerings. The highly versatile IDS i20 instrument allows users to simultaneously ru

      5/19/25 8:00:00 AM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $RVTY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Gonzales Anita covered exercise/tax liability with 33 shares, decreasing direct ownership by 0.73% to 4,489 units (SEC Form 4)

      4 - REVVITY, INC. (0000031791) (Issuer)

      6/17/25 4:05:04 PM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Mcmurry-Heath Michelle sold $55,299 worth of shares (600 units at $92.17), decreasing direct ownership by 11% to 4,833 units (SEC Form 4)

      4 - REVVITY, INC. (0000031791) (Issuer)

      5/30/25 4:06:32 PM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Vandebroek Sophie V. was granted 2,412 shares, increasing direct ownership by 90% to 5,088 units (SEC Form 4)

      4 - REVVITY, INC. (0000031791) (Issuer)

      5/1/25 4:05:18 PM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $RVTY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Revvity upgraded by UBS with a new price target

      UBS upgraded Revvity from Neutral to Buy and set a new price target of $115.00

      5/1/25 7:42:49 AM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Revvity downgraded by Bernstein with a new price target

      Bernstein downgraded Revvity from Outperform to Mkt Perform and set a new price target of $130.00

      1/10/25 8:41:17 AM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Revvity upgraded by BofA Securities with a new price target

      BofA Securities upgraded Revvity from Neutral to Buy and set a new price target of $138.00

      12/13/24 8:43:02 AM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $RVTY
    Financials

    Live finance-specific insights

    See more
    • Revvity Announces Financial Results for the First Quarter of 2025

      Revenue of $665 million; 2% reported growth; 4% organic growth GAAP EPS of $0.35; Adjusted EPS from continuing operations of $1.01 Reaffirms full year 2025 organic growth and adjusted EPS guidance Revvity, Inc. (NYSE:RVTY), today reported financial results for the first quarter ended March 30, 2025. The Company reported GAAP earnings per share of $0.35, as compared to $0.21 in the same period a year ago. Revenue for the quarter was $665 million, as compared to $650 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $72 million, as compared to $44 million for the same period a year ago. GAAP operating profit margin from continu

      4/28/25 6:00:00 AM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Revvity Board Declares Quarterly Dividend

      The Board of Directors of Revvity (NYSE:RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 8, 2025 to all shareholders of record at the close of business on July 18, 2025. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detec

      4/24/25 4:05:00 PM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Revvity to Hold Earnings Call on Monday, April 28, 2025

      Revvity, Inc. (NYSE:RVTY), today announced that it will release its first quarter 2025 financial results prior to market open on Monday, April 28, 2025. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Investors section of the Company's website. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows

      4/3/25 8:00:00 AM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $RVTY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Revvity Inc.

      SC 13G/A - REVVITY, INC. (0000031791) (Subject)

      11/14/24 4:30:07 PM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Revvity Inc.

      SC 13G/A - REVVITY, INC. (0000031791) (Subject)

      11/14/24 1:28:28 PM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by Revvity Inc.

      SC 13G - REVVITY, INC. (0000031791) (Subject)

      11/14/24 1:22:34 PM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials